Feedback / Questions
Retevmo (selpercatinib) - Eli Lilly
https://www.prnewswire.com/news-releases/lillys-retevmo-selpercatinib-delivers-substantial-event-free-survival-benefit-as-an-adjuvant-therapy-in-early-stage-ret-fusion-positive-lung-cancer-302687923.html
Feb 16, 2026
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next